<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-24900" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Medroxyprogesterone</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Sathe</surname>
            <given-names>Abha</given-names>
          </name>
          <aff>California Northstate University</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Patel</surname>
            <given-names>Preeti</given-names>
          </name>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Gerriets</surname>
            <given-names>Valerie</given-names>
          </name>
          <aff>California Northstate University College of Medicine</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Abha Sathe declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Preeti Patel declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Valerie Gerriets declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>29</day>
          <month>2</month>
          <year>2024</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-24900.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p content-type="pubmed-excerpt">Medroxyprogesterone&#x000a0;is used to prevent pregnancy in females of reproductive potential and for women experiencing amenorrhea due to hormonal imbalance, excluding organic pathologies such as fibroids and uterine cancer. Additionally,&#x000a0;medroxyprogesterone is used for abnormal uterine bleeding due to ovulatory dysfunction, prevention of endometrial hyperplasia, pain related to endometriosis, and in patients with inoperable, recurrent, and/or metastatic endometrial carcinoma as adjunctive and/or palliative treatment. Medroxyprogesterone, a progestin, is similar in structure to naturally occurring progesterone. The mechanism of action of progestin involves binding the progesterone receptor in the hypothalamus, female reproductive tract, and pituitary and inhibiting the secretion of gonadotropin-releasing hormone (GnRH).</p>
        <p>This&#x000a0;activity highlights medroxyprogesterone as contraception to prevent pregnancy&#x000a0;and discusses the mechanism of action, adverse effects, monitoring, and contraindications for medroxyprogesterone, as well as the importance of&#x000a0;regularly monitoring patients for&#x000a0;adverse effects. An interprofessional team comprising primary care, ob/gyn, or related specialties might provide the best recommendations.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify appropriate indications for medroxyprogesterone, including contraception, hormone replacement therapy, and management of abnormal uterine bleeding.</p></list-item><list-item><p>Screen patients for contraindications and potential risks associated with medroxyprogesterone use, such as thromboembolic disorders and hormone-sensitive cancers.</p></list-item><list-item><p>Assess patient response to medroxyprogesterone treatment and monitor for adverse effects or complications.</p></list-item><list-item><p>Implement&#x000a0;effective interprofessional collaboration regarding&#x000a0;the benefits, risks, potential adverse effects, and administration of medroxyprogesterone, ensuring informed decision-making.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=24900&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=24900">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-24900.s2" sec-type="Indications">
        <title>Indications</title>
        <p>Medroxyprogesterone, a synthetic progestin, is commonly prescribed for&#x000a0;the medical conditions described below.</p>
        <p>
<bold>Labeled Indications</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Contraception (104 mg/0.65 mL and 150 mg/mL injection): Medroxyprogesterone acetate (MPA) injection is used to prevent pregnancy in females of reproductive potential.<xref ref-type="bibr" rid="article-24900.r1">[1]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Amenorrhea, secondary (tablet): Women experiencing amenorrhea due to hormonal imbalance and not because of organic pathologies such as fibroids and uterine cancer.<xref ref-type="bibr" rid="article-24900.r2">[2]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Abnormal uterine bleeding (tablet): The American College of Obstetricians and Gynecologists (ACOG) recommends&#x000a0;medroxyprogesterone&#x000a0;for women experiencing abnormal bleeding due to&#x000a0;ovulatory dysfunction; use is not advised for organic pathologies such as fibroids and uterine cancer.<xref ref-type="bibr" rid="article-24900.r3">[3]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Endometrial hyperplasia prevention (tablet): Medroxyprogesterone&#x000a0;is administered to non-hysterectomized postmenopausal patients receiving a daily oral dose of estrogen of 0.625 mg.<xref ref-type="bibr" rid="article-24900.r4">[4]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Endometrial carcinoma (400 mg/mL injection or 100 mg tablet): In patients with inoperable, recurrent, and/or metastatic endometrial carcinoma,&#x000a0;medroxyprogesterone acetate is used as adjunctive and/or palliative treatment.<xref ref-type="bibr" rid="article-24900.r4">[4]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Endometriosis (104 mg/0.65 mL injection): Used in patients experiencing pain related to endometriosis.<xref ref-type="bibr" rid="article-24900.r5">[5]</xref></p>
          </list-item>
        </list>
        <p>
<bold>Off-Label Indications</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Acute abnormal uterine bleeding&#x000a0;<xref ref-type="bibr" rid="article-24900.r6">[6]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Endometrial hyperplasia<xref ref-type="bibr" rid="article-24900.r7">[7]</xref><xref ref-type="bibr" rid="article-24900.r8">[8]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Hot flashes&#x000a0;<xref ref-type="bibr" rid="article-24900.r9">[9]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Paraphilia/hypersexuality&#x000a0;<xref ref-type="bibr" rid="article-24900.r10">[10]</xref></p>
          </list-item>
        </list>
        <p>Some research indicates that women with sickle-cell disease are considered good candidates for&#x000a0;medroxyprogesterone; the drug&#x000a0;has been shown to reduce sickle-cell pain in women.<xref ref-type="bibr" rid="article-24900.r11">[11]</xref>&#x000a0;Medroxyprogesterone&#x000a0;is also considered to&#x000a0;cause&#x000a0;a decreased incidence of seizures in women with seizure disorders.<xref ref-type="bibr" rid="article-24900.r2">[2]</xref>&#x000a0;Due to its association with respiratory centers, medroxyprogesterone has been used to treat patients with COPD, hypercapnia, sleep apnea, and Pickwickian syndrome.<xref ref-type="bibr" rid="article-24900.r12">[12]</xref></p>
      </sec>
      <sec id="article-24900.s3" sec-type="Mechanism of Action">
        <title>Mechanism of Action</title>
        <p>Medroxyprogesterone is similar in structure to naturally occurring progesterone. The mechanism of action of progestin involves binding the progesterone receptor in the hypothalamus, female reproductive tract, and pituitary and inhibiting the secretion of gonadotropin-releasing hormone (GnRH).<xref ref-type="bibr" rid="article-24900.r1">[1]</xref>&#x000a0;By decreasing the frequency of release of GnRH,&#x000a0;medroxyprogesterone blunts the midcycle LH surge and prevents follicular maturation and ovulation. Medroxyprogesterone changes a proliferative endometrium to secretory endometrium, making implantation difficult. Finally,&#x000a0;medroxyprogesterone also impairs sperm migration into the uterus by increasing the viscosity of the cervical mucus.<xref ref-type="bibr" rid="article-24900.r1">[1]</xref></p>
        <p>In premenopausal women experiencing amenorrhea and irregular uterine bleeding,&#x000a0;medroxyprogesterone can be used to establish a normal menstrual cycle. Medroxyprogesterone also decreases endometrial growth in postmenopausal and menopausal women who receive estrogen therapy. Medroxyprogesterone acts on endometrial lesions and decreases endometrial-related pain in patients with endometriosis.<xref ref-type="bibr" rid="article-24900.r5">[5]</xref>&#x000a0;</p>
        <p>
<bold>Pharmacodynamics and Pharmacokinetics</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Absorption
<list list-type="bullet"><list-item><p>Oral: Rapid</p></list-item><list-item><p>IM: Slow</p></list-item></list>
</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Protein binding: 86% to 90% bound to albumin&#x000a0;<xref ref-type="bibr" rid="article-24900.r5">[5]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Metabolism: Hepatic through hydroxylation and conjugation</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Bioavailability: 0.6% to 10%</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Half-Life Elimination&#x000a0;<xref ref-type="bibr" rid="article-24900.r13">[13]</xref>
<list list-type="bullet"><list-item><p>Oral: 12 to 17 hours</p></list-item><list-item><p>IM: approximately 50 days</p></list-item><list-item><p>SQ:&#x000a0;approximately&#x000a0;43 days</p></list-item></list>
</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Time to Peak&#x000a0;
<list list-type="bullet"><list-item><p>Oral: 2 to 7 hours&#x000a0;<xref ref-type="bibr" rid="article-24900.r14">[14]</xref></p></list-item><list-item><p>IM: 3 weeks to reach Cmax of 1&#x000a0;to 7 ng/mL</p></list-item><list-item><p>SQ: 1 week to reach Cmax of&#x000a0;0.953 ng/mL&#x000a0;<xref ref-type="bibr" rid="article-24900.r5">[5]</xref></p></list-item></list>
</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Excretion: Urine as glucuronide conjugates with a small amount excreted as sulfates</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-24900.s4" sec-type="Administration">
        <title>Administration</title>
        <p>Specific dosing based on formulation and indication can be found in the drug's packaging information.</p>
        <p>
<bold>Dose Formulations</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>IM&#x000a0;suspension: 150 mg/mL (1 mL)&#x000a0;injection vial or a prefilled syringe</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>SQ&#x000a0;suspension: 104 mg/0.65 mL (0.65 mL)</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Tablet, oral: 2.5, 5, and 10 mg</p>
          </list-item>
        </list>
        <p>Medroxyprogesterone injection inhibits ovulation for 14 weeks and must be administered every&#x000a0;3 months (12 weeks) for continuous contraception. Administration can be either IM or SQ; severe adverse reactions can occur if administered IV.</p>
        <p>
<bold>Oral Administration</bold>
</p>
        <p>Medroxyprogesterone tablets can be ingested sublingually and without regard to meals.&#x000a0;</p>
        <p>
<bold>Injectable Administration</bold>
</p>
        <p>Inspect the product for discoloration and particulate matter before usage.&#x000a0;</p>
        <p>
<bold>Intramuscular Administration&#x000a0;(Contraceptive Injection Suspension)</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Administer the injection to the gluteal or deltoid region.&#x000a0;</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Shake the suspension before injecting.&#x000a0;</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Do not dilute the suspension before injecting.&#x000a0;</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Do&#x000a0;not administer&#x000a0;the drug IV.&#x000a0;</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Exclude the possibility of pregnancy, especially if 14 weeks have passed since the first dose.&#x000a0;</p>
          </list-item>
        </list>
        <p>
<bold>Subcutaneous Administration&#x000a0;(Contraceptive Injection Suspension)&#x000a0;</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Inject a prefilled syringe into the anterior thigh or abdomen at a 45-degree angle. Pull the skin away from the body before injecting the drug.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Shake the tube vigorously for 1 min before usage.&#x000a0;</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Press the area lightly but do not rub&#x000a0;it&#x000a0;after the injection.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Avoid giving this IM or IV.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Administer within&#x000a0;5 days of onset of menstrual bleeding.<xref ref-type="bibr" rid="article-24900.r15">[15]</xref></p>
          </list-item>
        </list>
        <p>
<bold>Specific Patient Population</bold>
</p>
        <p><bold>Hepatic impairment:</bold>&#x000a0;Medroxyprogesterone should not be administered to&#x000a0;patients with significant liver impairment. If&#x000a0;the patient develops jaundice or liver function disturbances,&#x000a0;the drug should be stopped.<xref ref-type="bibr" rid="article-24900.r16">[16]</xref></p>
        <p><bold>Renal impairment:</bold>&#x000a0;No dose adjustment recommendations are studied/provided in the manufacturer's prescribing label. Medroxyprogesterone can cause fluid retention, requiring caution in patients with preexisting kidney disease.</p>
        <p><bold>Pregnancy considerations:&#x000a0;</bold>Three percent&#x000a0;of the users experienced an unintended pregnancy, and efficacy was determined to be 99%. The drug is not recommended for women considering pregnancy soon as it may delay the return of fertility after discontinuation. Ectopic pregnancy has been reported with the use of medroxyprogesterone.<xref ref-type="bibr" rid="article-24900.r17">[17]</xref></p>
        <p><bold>Breastfeeding considerations:</bold> Breastfeeding women should not use medroxyprogesterone until&#x000a0;6 weeks postpartum in breastfeeding women, as infants are exposed to&#x000a0;medroxyprogesterone through breast milk.<xref ref-type="bibr" rid="article-24900.r18">[18]</xref></p>
        <p><bold>Pediatric patients:</bold>&#x000a0;Medroxyprogesterone use is not advised before menarche. Use is associated with a significant loss of bone mineral density, an important concern during adolescence and early adulthood.</p>
        <p><bold>Older patients:</bold>&#x000a0;Medroxyprogesterone has not been studied in postmenopausal women and is not indicated in this population.</p>
      </sec>
      <sec id="article-24900.s5" sec-type="Adverse Effects">
        <title>Adverse Effects</title>
        <p>Menstrual irregularities and weight gain are the most common adverse effects of medroxyprogesterone.<xref ref-type="bibr" rid="article-24900.r19">[19]</xref>&#x000a0;Regarding&#x000a0;weight gain, a&#x000a0;study reported that&#x000a0;medroxyprogesterone use increased by 1.61 in BMI and an average weight gain of 3.23 kg (7.11 lb).<xref ref-type="bibr" rid="article-24900.r20">[20]</xref>&#x000a0;Meanwhile,&#x000a0;57.3% of the patients receiving medroxyprogesterone reported irregular menses during the first year. Irregular bleeding decreases to 30% after 24 months and 10% after 24 months. Fifty-five percent of women report amenorrhea after 12 months of therapy, increasing&#x000a0;to 68% after&#x000a0;2 years.</p>
        <p>The following adverse effects of medroxyprogesterone contraceptive injection have been noted: oligomenorrhea, delayed return to fertility, prolonged anovulation (temporary infertility), unexpected pregnancy, uterine hyperplasia, genitourinary infections, vaginal cysts, vaginal and uterine hemorrhage. In females who utilize medroxyprogesterone tablets without estrogen for hormone replacement therapy, bleeding, spotting, changes in menstrual flow, changes in cervical erosion, and changes in cervical secretions have been reported.&#x000a0;</p>
        <p>Both genders reported experiencing changes in breast symptoms and sexual function. Females who used the medroxyprogesterone contraceptive injection reported breast pain (2.8%) and decreased libido (5.5%). Post-market reports with the injection usage determined other adverse effects such as breast lumps, changes in breast size, nipple bleeding, galactorrhea, dyspareunia, lactation suppression, and changes in libido.<xref ref-type="bibr" rid="article-24900.r21">[21]</xref>&#x000a0;</p>
        <p>Females who only use medroxyprogesterone (without estrogen) for hormone replacement therapy reported mastodynia or mastalgia (breast pain), galactorrhea, and breast tenderness. Patients who used medroxyprogesterone in addition to estrogen for hormone replacement therapy reported breast tenderness, nipple breast discharge, fibrocystic breast changes, and breast cancer. In males, impotence and a decrease in testosterone levels by 25% were reported when they received medroxyprogesterone for palliative reasons.&#x000a0;</p>
        <p>Angioedema, anaphylactic shock, and dermatologic reactions have been reported in users. Between 1% and 5% of the medroxyprogesterone users reported hot flashes and acne vulgaris. Alopecia was reported in 1.1% of patients who received contraceptive injections.</p>
        <p>Postmarketing reports of contraceptive injection recipients indicated the following adverse effects: angioedema, dry skin, increased body odor, hyperhidrosis, axillary swelling, melasma, scleroderma, and urticaria. In women who used medroxyprogesterone in addition to estrogen for hormone replacement therapy, the following adverse effects occurred: chloasma or melasma after discontinuation, erythema multiforme, erythema nodosum, and alopecia. In addition, fixed drug eruption to medroxyprogesterone has been reported.<xref ref-type="bibr" rid="article-24900.r22">[22]</xref></p>
        <p>Patients utilizing medroxyprogesterone contraceptive injections have reported dizziness (5.6%), insomnia (1% to 5%), nervousness (10.8%), depression (1% to 5%), anxiety or irritability (1% to 5%) and headaches (9% to 16.5%). If a patient experiences a headache or migraine with focal features consistent with cerebral ischemia, then discontinuation of medroxyprogesterone is recommended.<xref ref-type="bibr" rid="article-24900.r23">[23]</xref>&#x000a0;</p>
        <p>CNS adverse effects such as facial palsy, syncope, paralysis, and paresthesia have also occurred with contraceptive injection usage. In women utilizing medroxyprogesterone tablets along with estrogen, chorea and mood disturbances have been reported. Women utilizing the IM depot contraceptive injection reported gastrointestinal effects such as abdominal pain, nausea, and bloating. A rare case of splenic artery thrombosis has been reported.<xref ref-type="bibr" rid="article-24900.r24">[24]</xref>&#x000a0;Progestins stimulate the respiratory center and, as a result, during pregnancy and women's luteal phase of the menstrual cycle. Consequently,&#x000a0;medroxyprogesterone can cause hyperventilation resulting in&#x000a0;hypocapnia due to elevated levels of endogenous progestins. A study conducted in Thailand reported that pregnant women who took&#x000a0;medroxyprogesterone had infants with&#x000a0;polysyndactyly. The study also determined that the infants of these mothers were at an increased risk of having chromosomal abnormalities.<xref ref-type="bibr" rid="article-24900.r2">[2]</xref><xref ref-type="bibr" rid="article-24900.r25">[25]</xref><xref ref-type="bibr" rid="article-24900.r2">[2]</xref></p>
        <p>
<bold>Drug-Drug Interactions</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>In vitro,&#x000a0;medroxyprogesterone is metabolized by CYP3A4. Therefore, inducers and inhibitors of CYP3A4 can affect the metabolism of medroxyprogesterone.<xref ref-type="bibr" rid="article-24900.r26">[26]</xref>&#x000a0;Drugs&#x000a0;that can reduce the&#x000a0;efficacy of medroxyprogesterone include barbiturates, carbamazepine,&#x000a0;oxcarbazepine, griseofulvin, bosentan, phenytoin, St. John&#x02019;s wort, rifampin, and topiramate.<xref ref-type="bibr" rid="article-24900.r27">[27]</xref><xref ref-type="bibr" rid="article-24900.r28">[28]</xref><xref ref-type="bibr" rid="article-24900.r29">[29]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Product labeling&#x000a0;specifies&#x000a0;that significant&#x000a0;changes&#x000a0;(increase or decrease) in the plasma&#x000a0;concentration of progestin have been&#x000a0;marked&#x000a0;with the coadministration of HIV protease inhibitors and non-nucleoside reverse transcriptase inhibitors (NNRTIs) with medroxyprogesterone. Use with caution.<xref ref-type="bibr" rid="article-24900.r30">[30]</xref><xref ref-type="bibr" rid="article-24900.r31">[31]</xref><xref ref-type="bibr" rid="article-24900.r32">[32]</xref></p>
          </list-item>
        </list>
        <p>
<bold>Drug-Laboratory&#x000a0;Interference</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Gonadotropin levels&#x000a0;are reduced, and sex hormone-binding globulin is increased.<xref ref-type="bibr" rid="article-24900.r33">[33]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Administration of&#x000a0;medroxyprogesterone can increase&#x000a0;total T4, total T3, and thyroid-binding globulin levels; T3 uptake is also altered.<xref ref-type="bibr" rid="article-24900.r34">[34]</xref></p>
          </list-item>
        </list>
      </sec>
      <sec id="article-24900.s6" sec-type="Contraindications">
        <title>Contraindications</title>
        <p>Medroxyprogesterone is contraindicated in patients with known hypersensitivity to the drug or its excipients. Cases of angioedema and anaphylactic reaction have occurred in patients utilizing medroxyprogesterone.<xref ref-type="bibr" rid="article-24900.r35">[35]</xref>&#x000a0;Both forms of the drug (oral and injection) are contraindicated in patients with pre-existing breast cancer. In patients with a history of breast cancer, renal cancer, endometrial cancer, or a family history of breast cancer, medroxyprogesterone is contraindicated. Medroxyprogesterone injection has shown a slightly increased risk of developing breast cancer.<xref ref-type="bibr" rid="article-24900.r36">[36]</xref><xref ref-type="bibr" rid="article-24900.r37">[37]</xref><xref ref-type="bibr" rid="article-24900.r38">[38]</xref>&#x000a0;Medroxyprogesterone is contraindicated in patients with undiagnosed vaginal bleeding.</p>
        <p>Medroxyprogesterone use requires caution in patients with diabetes. Hormonal contraceptives have been known to alter insulin sensitivity and, as a result, glucose tolerance. Medroxyprogesterone injections are contraindicated in patients with a history of arterial or venous thromboembolic (VTE) diseases or with an increased risk for stroke, heart disease, and arterial vascular disease.<xref ref-type="bibr" rid="article-24900.r23">[23]</xref> Hormonal contraceptives can cause fluid retention and, as a result, should be used with caution in patients with asthma, congestive heart failure, and nephrotic syndrome.&#x000a0;</p>
        <p>When using medroxyprogesterone in postmenopausal women along with estrogen therapy, it is associated with cardiovascular and thromboembolic risks.<xref ref-type="bibr" rid="article-24900.r2">[2]</xref> Medroxyprogesterone use requires caution in women with hypertension, and blood pressure&#x000a0;requires regular monitoring. Though estrogen-progestin combinations are known to alter serum lipid levels, it is essential to be cautious about medroxyprogesterone, a progestin-only contraceptive. Therefore,&#x000a0;clinicians should check HDL and LDL regularly in patients. Although no congenital disabilities have been noted in patients exposed to medroxyprogesterone, it is contraindicated in pregnancy or suspected pregnancy.</p>
        <p>The suspension injections can induce temporary infertility at higher concentrations, and patients experience delays in returning to baseline after&#x000a0;ceasing treatment. Medroxyprogesterone tablets are also contraindicated in patients with incomplete abortions. In women with hepatic dysfunction or hepatic diseases, medroxyprogesterone usage is contraindicated. Use should be discontinued in women who experience jaundice or disturbances with their liver function. In women with a history of major depression, migraine, or seizure disorder, medroxyprogesterone should be used with caution, as progestin can exacerbate these conditions.&#x000a0; Clinicians&#x000a0;should counsel patients that using medroxyprogesterone does not protect against human immunodeficiency virus (HIV) infection or other sexually transmitted diseases.<xref ref-type="bibr" rid="article-24900.r39">[39]</xref></p>
        <p>
<bold>Box Warnings</bold>
</p>
        <p>Estrogens and progestins should not be used&#x000a0;for cardiovascular disease prophylaxis.</p>
        <list list-type="bullet">
          <list-item>
            <p>An increased risk of myocardial infarction, pulmonary embolism,&#x000a0;deep vein thrombosis, and stroke in postmenopausal women (50&#x000a0;to 79 years) is seen with&#x000a0;prolonged treatment when&#x000a0;medroxyprogesterone is combined with&#x000a0;conjugated estrogens.<xref ref-type="bibr" rid="article-24900.r40">[40]</xref><xref ref-type="bibr" rid="article-24900.r41">[41]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>MPA&#x000a0;depot injection can&#x000a0;decrease bone mineral density, possibly irreversible in postmenopausal women. Calcium and vitamin D&#x000a0;supplementation are recommended.<xref ref-type="bibr" rid="article-24900.r42">[42]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>MPA&#x000a0;injection&#x000a0;is not advised as a long-term (ie,&#x000a0;older than&#x000a0;2 years) birth control; and should be utilized only when other birth control options are deemed inadequate.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>A&#x000a0;risk of dementia in postmenopausal women 65 years and older during&#x000a0;4 years of daily treatment with conjugated estrogen&#x000a0;plus medroxyprogesterone is evident.<xref ref-type="bibr" rid="article-24900.r43">[43]</xref><xref ref-type="bibr" rid="article-24900.r44">[44]</xref></p>
          </list-item>
        </list>
      </sec>
      <sec id="article-24900.s7" sec-type="Monitoring">
        <title>Monitoring</title>
        <p>Patients require evaluation regarding their pregnancy status before starting therapy and if 14 weeks have passed since the last injection. Also, weight and bone mineral density should be evaluated&#x000a0;regularly; consider bone mineral density in female patients with a strong history of breast cancer and the possibility of developing endometrial cancer, especially with long-term medroxyprogesterone use. Endometrial sampling is recommended every 3&#x000a0;to 5 months to monitor continually for endometrial hyperplasia.<xref ref-type="bibr" rid="article-24900.r45">[45]</xref><xref ref-type="bibr" rid="article-24900.r7">[7]</xref></p>
        <p>For menopausal patients currently using combination hormonal therapy, the risk for breast cancer and cardiovascular disease&#x000a0;requires assessment.&#x000a0;After initiating&#x000a0;medroxyprogesterone therapy,&#x000a0;the healthcare team must assess blood pressure and any unscheduled bleeding of greater than&#x000a0;6 months duration to evaluate for endometrial pathology. Additionally, patients should be administered breast exams and pelvic exams, depending on their age. These parameters should be followed even more closely for patients with diabetes, obesity, or a family history of endometrial cancer. Serum triglycerides should be monitored closely and checked&#x000a0;2 weeks after initiating therapy in patients with elevated triglycerides (&#x0003e;200 mg/dL). For patients currently&#x000a0;receiving thyroid replacements, TSH levels must also be monitored 6&#x000a0;to 12 weeks after starting on oral medroxyprogesterone tablets.<xref ref-type="bibr" rid="article-24900.r9">[9]</xref>&#x000a0;If patients are currently prescribed&#x000a0;medroxyprogesterone for paraphilia/hypersexuality, liver function tests (LFTs), complete blood count (CBC), serum testosterone, LH, FSH, and glucose require regular monitoring. Also, consider an annual bone scan if serum testosterone markedly decreases.<xref ref-type="bibr" rid="article-24900.r46">[46]</xref><xref ref-type="bibr" rid="article-24900.r47">[47]</xref></p>
      </sec>
      <sec id="article-24900.s8" sec-type="Toxicity">
        <title>Toxicity</title>
        <p>Patients experiencing&#x000a0;medroxyprogesterone&#x000a0;overdose may experience nausea, vomiting, seizures, trouble breathing, and altered mental status. Treatment is primarily supportive.</p>
      </sec>
      <sec id="article-24900.s9" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Medroxyprogesterone can be administered via injection or oral tablet. Administering&#x000a0;medroxyprogesterone&#x000a0;requires communication between all interprofessional healthcare team members. Communication includes providing detailed instructions on different ways of administering IM and SQ injections and avoiding IV administration altogether. Additionally, clinicians and pharmacists must work together to determine appropriate forms of medroxyprogesterone, given the patient's symptoms and diagnosis. This level of collaboration can assist in avoiding adverse effects on patients and the potential development of invasive cancers and involves the entire interprofessional team.&#x000a0;Pharmacists should&#x000a0;verify&#x000a0;the prescription before dispensing, as&#x000a0;medroxyprogesterone&#x000a0;can be confused with methyltestosterone and methylprednisolone.<xref ref-type="bibr" rid="article-24900.r48">[48]</xref>&#x000a0;They should also verify dosing and administration techniques, perform medication reconciliation, and offer patient counseling regarding their prescription.</p>
        <p>Nursing staff&#x000a0;and other healthcare team members need training in treating contraceptive overdose and the symptoms that could point in the direction of overdose. Nurses and other clinicians in the emergency department (ED) must work together to obtain drug levels in the blood and treat them to prevent any immediate adverse effects resulting from the overdose. To treat any long-term symptoms of the overdose, the healthcare team in the ED should consult with a toxicologist and pharmacist to provide evidence-based medical intervention.<xref ref-type="bibr" rid="article-24900.r49">[49]</xref></p>
        <p>Medical staff should be prepared to inform patients about long-term usage risks and adverse effects. The healthcare team must work together to educate women with accurate information and, in the process,&#x000a0;counter the inaccurate information spread through magazines and other patient-friendly lay platforms.<xref ref-type="bibr" rid="article-24900.r19">[19]</xref>&#x000a0;Patients should&#x000a0;obtain counsel regarding the risk of osteoporosis and be screened regularly for breast cancer. They should also be informed about the likely menstrual disturbances and their length.<xref ref-type="bibr" rid="article-24900.r50">[50]</xref>&#x000a0;The interprofessional efforts of primary care clinicians, gynecologists, advanced practice practitioners, pharmacists, nursing staff, and pharmacists can improve therapeutic outcomes while minimizing adverse patient events when using medroxyprogesterone.</p>
      </sec>
      <sec id="article-24900.s10">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=24900&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=24900">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/24900/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=24900">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-24900.s11">
        <title>References</title>
        <ref id="article-24900.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mishell</surname>
                <given-names>DR</given-names>
              </name>
            </person-group>
            <article-title>Pharmacokinetics of depot medroxyprogesterone acetate contraception.</article-title>
            <source>J Reprod Med</source>
            <year>1996</year>
            <month>May</month>
            <volume>41</volume>
            <issue>5 Suppl</issue>
            <fpage>381</fpage>
            <page-range>381-90</page-range>
            <pub-id pub-id-type="pmid">8725700</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24900.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Westhoff</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Depot-medroxyprogesterone acetate injection (Depo-Provera): a highly effective contraceptive option with proven long-term safety.</article-title>
            <source>Contraception</source>
            <year>2003</year>
            <month>Aug</month>
            <volume>68</volume>
            <issue>2</issue>
            <fpage>75</fpage>
            <page-range>75-87</page-range>
            <pub-id pub-id-type="pmid">12954518</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24900.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <article-title>Practice bulletin no. 136: management of abnormal uterine bleeding associated with ovulatory dysfunction.</article-title>
            <source>Obstet Gynecol</source>
            <year>2013</year>
            <month>Jul</month>
            <volume>122</volume>
            <issue>1</issue>
            <fpage>176</fpage>
            <page-range>176-185</page-range>
            <pub-id pub-id-type="pmid">23787936</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24900.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tamauchi</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Kajiyama</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Utsumi</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Suzuki</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Niimi</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Sakata</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Mizuno</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Shibata</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Kikkawa</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>Efficacy of medroxyprogesterone acetate treatment and retreatment for atypical endometrial hyperplasia and endometrial cancer.</article-title>
            <source>J Obstet Gynaecol Res</source>
            <year>2018</year>
            <month>Jan</month>
            <volume>44</volume>
            <issue>1</issue>
            <fpage>151</fpage>
            <page-range>151-156</page-range>
            <pub-id pub-id-type="pmid">29121428</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24900.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Barra</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Scala</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Ferrero</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Current understanding on pharmacokinetics, clinical efficacy and safety of progestins for treating pain associated to endometriosis.</article-title>
            <source>Expert Opin Drug Metab Toxicol</source>
            <year>2018</year>
            <month>Apr</month>
            <volume>14</volume>
            <issue>4</issue>
            <fpage>399</fpage>
            <page-range>399-415</page-range>
            <pub-id pub-id-type="pmid">29617576</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24900.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Munro</surname>
                <given-names>MG</given-names>
              </name>
              <name>
                <surname>Mainor</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Basu</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Brisinger</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Barreda</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>Oral medroxyprogesterone acetate and combination oral contraceptives for acute uterine bleeding: a randomized controlled trial.</article-title>
            <source>Obstet Gynecol</source>
            <year>2006</year>
            <month>Oct</month>
            <volume>108</volume>
            <issue>4</issue>
            <fpage>924</fpage>
            <page-range>924-9</page-range>
            <pub-id pub-id-type="pmid">17012455</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24900.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <article-title>The American College of Obstetricians and Gynecologists Committee Opinion no. 631. Endometrial intraepithelial neoplasia.</article-title>
            <source>Obstet Gynecol</source>
            <year>2015</year>
            <month>May</month>
            <volume>125</volume>
            <issue>5</issue>
            <fpage>1272</fpage>
            <page-range>1272-1278</page-range>
            <pub-id pub-id-type="pmid">25932867</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24900.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>De Rocco</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Buca</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Oronzii</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Petrillo</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Fanfani</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Nappi</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Liberati</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>D'Antonio</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Scambia</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Leombroni</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Dessole</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Lucidi</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Reproductive and pregnancy outcomes of fertility-sparing treatments for early-stage endometrial cancer or atypical hyperplasia: A systematic review and meta-analysis.</article-title>
            <source>Eur J Obstet Gynecol Reprod Biol</source>
            <year>2022</year>
            <month>Jun</month>
            <volume>273</volume>
            <fpage>90</fpage>
            <page-range>90-97</page-range>
            <pub-id pub-id-type="pmid">35526471</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24900.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Stuenkel</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>Davis</surname>
                <given-names>SR</given-names>
              </name>
              <name>
                <surname>Gompel</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Lumsden</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Murad</surname>
                <given-names>MH</given-names>
              </name>
              <name>
                <surname>Pinkerton</surname>
                <given-names>JV</given-names>
              </name>
              <name>
                <surname>Santen</surname>
                <given-names>RJ</given-names>
              </name>
            </person-group>
            <article-title>Treatment of Symptoms of the Menopause: An Endocrine Society Clinical Practice Guideline.</article-title>
            <source>J Clin Endocrinol Metab</source>
            <year>2015</year>
            <month>Nov</month>
            <volume>100</volume>
            <issue>11</issue>
            <fpage>3975</fpage>
            <page-range>3975-4011</page-range>
            <pub-id pub-id-type="pmid">26444994</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24900.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Berlin</surname>
                <given-names>FS</given-names>
              </name>
            </person-group>
            <article-title>The paraphilias and Depo-Provera: some medical, ethical and legal considerations.</article-title>
            <source>Bull Am Acad Psychiatry Law</source>
            <year>1989</year>
            <volume>17</volume>
            <issue>3</issue>
            <fpage>233</fpage>
            <page-range>233-9</page-range>
            <pub-id pub-id-type="pmid">2529006</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24900.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>De Ceulaer</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Gruber</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Hayes</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Serjeant</surname>
                <given-names>GR</given-names>
              </name>
            </person-group>
            <article-title>Medroxyprogesterone acetate and homozygous sickle-cell disease.</article-title>
            <source>Lancet</source>
            <year>1982</year>
            <month>Jul</month>
            <day>31</day>
            <volume>2</volume>
            <issue>8292</issue>
            <fpage>229</fpage>
            <page-range>229-31</page-range>
            <pub-id pub-id-type="pmid">6178915</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24900.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sutton</surname>
                <given-names>FD</given-names>
              </name>
              <name>
                <surname>Zwillich</surname>
                <given-names>CW</given-names>
              </name>
              <name>
                <surname>Creagh</surname>
                <given-names>CE</given-names>
              </name>
              <name>
                <surname>Pierson</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>Weil</surname>
                <given-names>JV</given-names>
              </name>
            </person-group>
            <article-title>Progesterone for outpatient treatment of Pickwickian syndrome.</article-title>
            <source>Ann Intern Med</source>
            <year>1975</year>
            <month>Oct</month>
            <volume>83</volume>
            <issue>4</issue>
            <fpage>476</fpage>
            <page-range>476-9</page-range>
            <pub-id pub-id-type="pmid">1101759</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24900.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Stockdale</surname>
                <given-names>AD</given-names>
              </name>
              <name>
                <surname>Rostom</surname>
                <given-names>AY</given-names>
              </name>
            </person-group>
            <article-title>Clinical significance of differences in bioavailability of medroxyprogesterone acetate preparations.</article-title>
            <source>Clin Pharmacokinet</source>
            <year>1989</year>
            <month>Mar</month>
            <volume>16</volume>
            <issue>3</issue>
            <fpage>129</fpage>
            <page-range>129-33</page-range>
            <pub-id pub-id-type="pmid">2524303</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24900.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>L&#x000f8;ber</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Mouridsen</surname>
                <given-names>HT</given-names>
              </name>
              <name>
                <surname>Salimtschik</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Johansson</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>Pharmacokinetics of medroxyprogesterone acetate administered by oral and intramuscular route.</article-title>
            <source>Acta Obstet Gynecol Scand Suppl</source>
            <year>1981</year>
            <volume>101</volume>
            <fpage>71</fpage>
            <page-range>71-4</page-range>
            <pub-id pub-id-type="pmid">6946675</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24900.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Halpern</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Combes</surname>
                <given-names>SL</given-names>
              </name>
              <name>
                <surname>Dorflinger</surname>
                <given-names>LJ</given-names>
              </name>
              <name>
                <surname>Weiner</surname>
                <given-names>DH</given-names>
              </name>
              <name>
                <surname>Archer</surname>
                <given-names>DF</given-names>
              </name>
            </person-group>
            <article-title>Pharmacokinetics of subcutaneous depot medroxyprogesterone acetate injected in the upper arm.</article-title>
            <source>Contraception</source>
            <year>2014</year>
            <month>Jan</month>
            <volume>89</volume>
            <issue>1</issue>
            <fpage>31</fpage>
            <page-range>31-5</page-range>
            <pub-id pub-id-type="pmid">23993431</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24900.r16">
          <label>16</label>
          <element-citation publication-type="book">
            <chapter-title>Progestins</chapter-title>
            <source>LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]</source>
            <publisher-name>National Institute of Diabetes and Digestive and Kidney Diseases</publisher-name>
            <publisher-loc>Bethesda (MD)</publisher-loc>
            <year>2020</year>
            <month>6</month>
            <day>1</day>
            <pub-id pub-id-type="pmid">31643562</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24900.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Assouni Mindjah</surname>
                <given-names>YA</given-names>
              </name>
              <name>
                <surname>Essiben</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Foumane</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Dohbit</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Mboudou</surname>
                <given-names>ET</given-names>
              </name>
            </person-group>
            <article-title>Risk factors for ectopic pregnancy in a population of Cameroonian women: A case-control study.</article-title>
            <source>PLoS One</source>
            <year>2018</year>
            <volume>13</volume>
            <issue>12</issue>
            <fpage>e0207699</fpage>
            <pub-id pub-id-type="pmid">30540783</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24900.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Koetsawang</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Nukulkarn</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Fotherby</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Shrimanker</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Mangalam</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Towobola</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Transfer of contraceptive steroids in milk of women using long-acting gestagens.</article-title>
            <source>Contraception</source>
            <year>1982</year>
            <month>Apr</month>
            <volume>25</volume>
            <issue>4</issue>
            <fpage>321</fpage>
            <page-range>321-31</page-range>
            <pub-id pub-id-type="pmid">6213373</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24900.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bigrigg</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Evans</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Gbolade</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Newton</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Pollard</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Szarewski</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Thomas</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Walling</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Depo Provera. Position paper on clinical use, effectiveness and side effects.</article-title>
            <source>Br J Fam Plann</source>
            <year>1999</year>
            <month>Jul</month>
            <volume>25</volume>
            <issue>2</issue>
            <fpage>69</fpage>
            <page-range>69-76</page-range>
            <pub-id pub-id-type="pmid">10454658</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24900.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mesics</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Depo-Provera.</article-title>
            <source>AWHONN Lifelines</source>
            <year>2002</year>
            <season>Apr-May</season>
            <volume>6</volume>
            <issue>2</issue>
            <fpage>93</fpage>
            <pub-id pub-id-type="pmid">11975135</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24900.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <collab>ACOG Committee on Practice Bulletins-Gynecology</collab>
            <article-title>ACOG practice bulletin. No. 73: Use of hormonal contraception in women with coexisting medical conditions.</article-title>
            <source>Obstet Gynecol</source>
            <year>2006</year>
            <month>Jun</month>
            <volume>107</volume>
            <issue>6</issue>
            <fpage>1453</fpage>
            <page-range>1453-72</page-range>
            <pub-id pub-id-type="pmid">16738183</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24900.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Patel</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Cervantes</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Keeling</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Adamson</surname>
                <given-names>AS</given-names>
              </name>
            </person-group>
            <article-title>A Fixed Drug Eruption to Medroxyprogesterone Acetate Injectable Suspension.</article-title>
            <source>Cutis</source>
            <year>2022</year>
            <month>Mar</month>
            <volume>109</volume>
            <issue>3</issue>
            <fpage>E12</fpage>
            <page-range>E12-E14</page-range>
            <pub-id pub-id-type="pmid">35659137</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24900.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Curtis</surname>
                <given-names>KM</given-names>
              </name>
              <name>
                <surname>Tepper</surname>
                <given-names>NK</given-names>
              </name>
              <name>
                <surname>Jatlaoui</surname>
                <given-names>TC</given-names>
              </name>
              <name>
                <surname>Berry-Bibee</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Horton</surname>
                <given-names>LG</given-names>
              </name>
              <name>
                <surname>Zapata</surname>
                <given-names>LB</given-names>
              </name>
              <name>
                <surname>Simmons</surname>
                <given-names>KB</given-names>
              </name>
              <name>
                <surname>Pagano</surname>
                <given-names>HP</given-names>
              </name>
              <name>
                <surname>Jamieson</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>Whiteman</surname>
                <given-names>MK</given-names>
              </name>
            </person-group>
            <article-title>U.S. Medical Eligibility Criteria for Contraceptive Use, 2016.</article-title>
            <source>MMWR Recomm Rep</source>
            <year>2016</year>
            <month>Jul</month>
            <day>29</day>
            <volume>65</volume>
            <issue>3</issue>
            <fpage>1</fpage>
            <page-range>1-103</page-range>
            <pub-id pub-id-type="pmid">27467196</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24900.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Haider</surname>
                <given-names>AA</given-names>
              </name>
              <name>
                <surname>Bassi</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Prakash</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Hussein</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Alzghoul</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Bilal</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Oyetoran</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Iyer</surname>
                <given-names>UG</given-names>
              </name>
            </person-group>
            <article-title>A Rare Case of Splenic Artery Thrombosis Provoked By Medroxyprogesterone Acetate Requiring Splenectomy.</article-title>
            <source>Cureus</source>
            <year>2023</year>
            <month>Jan</month>
            <volume>15</volume>
            <issue>1</issue>
            <fpage>e33880</fpage>
            <pub-id pub-id-type="pmid">36819368</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24900.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gray</surname>
                <given-names>RH</given-names>
              </name>
              <name>
                <surname>Pardthaisong</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>In utero exposure to steroid contraceptives and survival during infancy.</article-title>
            <source>Am J Epidemiol</source>
            <year>1991</year>
            <month>Oct</month>
            <day>15</day>
            <volume>134</volume>
            <issue>8</issue>
            <fpage>804</fpage>
            <page-range>804-11</page-range>
            <pub-id pub-id-type="pmid">1835283</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24900.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mimura</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Kobayashi</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Nakamura</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Shimada</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Hosokawa</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Chiba</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Metabolism of medroxyprogesterone acetate (MPA) via CYP enzymes in vitro and effect of MPA on bleeding time in female rats in dependence on CYP activity in vivo.</article-title>
            <source>Life Sci</source>
            <year>2003</year>
            <month>Nov</month>
            <day>07</day>
            <volume>73</volume>
            <issue>25</issue>
            <fpage>3201</fpage>
            <page-range>3201-12</page-range>
            <pub-id pub-id-type="pmid">14561525</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24900.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wiesinger</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Klein</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Rottmann</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Nowotny</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Riecke</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Gashaw</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Brudny-Kl&#x000f6;ppel</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Fricke</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>H&#x000f6;chel</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Friedrich</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>The Effects of Weak and Strong CYP3A Induction by Rifampicin on the Pharmacokinetics of Five Progestins and Ethinylestradiol Compared to Midazolam.</article-title>
            <source>Clin Pharmacol Ther</source>
            <year>2020</year>
            <month>Oct</month>
            <volume>108</volume>
            <issue>4</issue>
            <fpage>798</fpage>
            <page-range>798-807</page-range>
            <pub-id pub-id-type="pmid">32275771</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24900.r28">
          <label>28</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Venitz</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Zack</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Gillies</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Allard</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Regnault</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Dufton</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Clinical pharmacokinetics and drug-drug interactions of endothelin receptor antagonists in pulmonary arterial hypertension.</article-title>
            <source>J Clin Pharmacol</source>
            <year>2012</year>
            <month>Dec</month>
            <volume>52</volume>
            <issue>12</issue>
            <fpage>1784</fpage>
            <page-range>1784-805</page-range>
            <pub-id pub-id-type="pmid">22205719</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24900.r29">
          <label>29</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Doose</surname>
                <given-names>DR</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>SS</given-names>
              </name>
              <name>
                <surname>Padmanabhan</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Schwabe</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Jacobs</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Bialer</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Effect of topiramate or carbamazepine on the pharmacokinetics of an oral contraceptive containing norethindrone and ethinyl estradiol in healthy obese and nonobese female subjects.</article-title>
            <source>Epilepsia</source>
            <year>2003</year>
            <month>Apr</month>
            <volume>44</volume>
            <issue>4</issue>
            <fpage>540</fpage>
            <page-range>540-9</page-range>
            <pub-id pub-id-type="pmid">12681003</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24900.r30">
          <label>30</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tseng</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Hills-Nieminen</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Drug interactions between antiretrovirals and hormonal contraceptives.</article-title>
            <source>Expert Opin Drug Metab Toxicol</source>
            <year>2013</year>
            <month>May</month>
            <volume>9</volume>
            <issue>5</issue>
            <fpage>559</fpage>
            <page-range>559-72</page-range>
            <pub-id pub-id-type="pmid">23425052</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24900.r31">
          <label>31</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Haas</surname>
                <given-names>DW</given-names>
              </name>
              <name>
                <surname>Mngqibisa</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Francis</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>McIlleron</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Robinson</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Kendall</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Baker</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Mawlana</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Badal-Faesen</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Angira</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Omoz-Oarhe</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Samaneka</surname>
                <given-names>WP</given-names>
              </name>
              <name>
                <surname>Denti</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Cohn</surname>
                <given-names>SE</given-names>
              </name>
              <collab>AIDS Clinical Trials Group A5338 Study Team</collab>
            </person-group>
            <article-title>Pharmacogenetics of interaction between depot medroxyprogesterone acetate and efavirenz, rifampicin, and isoniazid during treatment of HIV and tuberculosis.</article-title>
            <source>Pharmacogenet Genomics</source>
            <year>2022</year>
            <month>Jan</month>
            <day>01</day>
            <volume>32</volume>
            <issue>1</issue>
            <fpage>24</fpage>
            <page-range>24-30</page-range>
            <pub-id pub-id-type="pmid">34369424</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24900.r32">
          <label>32</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nanda</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Stuart</surname>
                <given-names>GS</given-names>
              </name>
              <name>
                <surname>Robinson</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Gray</surname>
                <given-names>AL</given-names>
              </name>
              <name>
                <surname>Tepper</surname>
                <given-names>NK</given-names>
              </name>
              <name>
                <surname>Gaffield</surname>
                <given-names>ME</given-names>
              </name>
            </person-group>
            <article-title>Drug interactions between hormonal contraceptives and antiretrovirals.</article-title>
            <source>AIDS</source>
            <year>2017</year>
            <month>Apr</month>
            <day>24</day>
            <volume>31</volume>
            <issue>7</issue>
            <fpage>917</fpage>
            <page-range>917-952</page-range>
            <pub-id pub-id-type="pmid">28060009</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24900.r33">
          <label>33</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Saaresranta</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Irjala</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Polo-Kantola</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Helenius</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Polo</surname>
                <given-names>O</given-names>
              </name>
            </person-group>
            <article-title>Prolonged endocrine responses to medroxyprogesterone in postmenopausal women with respiratory insufficiency.</article-title>
            <source>Obstet Gynecol</source>
            <year>2000</year>
            <month>Aug</month>
            <volume>96</volume>
            <issue>2</issue>
            <fpage>243</fpage>
            <page-range>243-9</page-range>
            <pub-id pub-id-type="pmid">10908771</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24900.r34">
          <label>34</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ren</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Zhou</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Hu</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Zhong</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Lv</surname>
                <given-names>Q</given-names>
              </name>
              <name>
                <surname>Xie</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Yang</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Zhu</surname>
                <given-names>Y</given-names>
              </name>
            </person-group>
            <article-title>Thyroid Hormone Receptor &#x003b2; Knockdown Reduces Suppression of Progestins by Activating the mTOR Pathway in Endometrial Cancer Cells.</article-title>
            <source>Int J Mol Sci</source>
            <year>2022</year>
            <month>Oct</month>
            <day>19</day>
            <volume>23</volume>
            <issue>20</issue>
            <pub-id pub-id-type="pmid">36293372</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24900.r35">
          <label>35</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lestishock</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Pariseau</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Rooholamini</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Ammerman</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Anaphylaxis from depot medroxyprogesterone acetate in an adolescent girl.</article-title>
            <source>Obstet Gynecol</source>
            <year>2011</year>
            <month>Aug</month>
            <volume>118</volume>
            <issue>2 Pt 2</issue>
            <fpage>443</fpage>
            <page-range>443-445</page-range>
            <pub-id pub-id-type="pmid">21768848</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24900.r36">
          <label>36</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Li</surname>
                <given-names>CI</given-names>
              </name>
              <name>
                <surname>Beaber</surname>
                <given-names>EF</given-names>
              </name>
              <name>
                <surname>Tang</surname>
                <given-names>MT</given-names>
              </name>
              <name>
                <surname>Porter</surname>
                <given-names>PL</given-names>
              </name>
              <name>
                <surname>Daling</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Malone</surname>
                <given-names>KE</given-names>
              </name>
            </person-group>
            <article-title>Effect of depo-medroxyprogesterone acetate on breast cancer risk among women 20 to 44 years of age.</article-title>
            <source>Cancer Res</source>
            <year>2012</year>
            <month>Apr</month>
            <day>15</day>
            <volume>72</volume>
            <issue>8</issue>
            <fpage>2028</fpage>
            <page-range>2028-35</page-range>
            <pub-id pub-id-type="pmid">22369929</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24900.r37">
          <label>37</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cobin</surname>
                <given-names>RH</given-names>
              </name>
              <name>
                <surname>Goodman</surname>
                <given-names>NF</given-names>
              </name>
              <collab>AACE Reproductive Endocrinology Scientific Committee</collab>
            </person-group>
            <article-title>AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY POSITION STATEMENT ON MENOPAUSE-2017 UPDATE.</article-title>
            <source>Endocr Pract</source>
            <year>2017</year>
            <month>Jul</month>
            <volume>23</volume>
            <issue>7</issue>
            <fpage>869</fpage>
            <page-range>869-880</page-range>
            <pub-id pub-id-type="pmid">28703650</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24900.r38">
          <label>38</label>
          <element-citation publication-type="journal">
            <collab>The NAMS 2017 Hormone Therapy Position Statement Advisory Panel</collab>
            <article-title>The 2017 hormone therapy position statement of The North American Menopause Society.</article-title>
            <source>Menopause</source>
            <year>2017</year>
            <month>Jul</month>
            <volume>24</volume>
            <issue>7</issue>
            <fpage>728</fpage>
            <page-range>728-753</page-range>
            <pub-id pub-id-type="pmid">28650869</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24900.r39">
          <label>39</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tepper</surname>
                <given-names>NK</given-names>
              </name>
              <name>
                <surname>Krashin</surname>
                <given-names>JW</given-names>
              </name>
              <name>
                <surname>Curtis</surname>
                <given-names>KM</given-names>
              </name>
              <name>
                <surname>Cox</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Whiteman</surname>
                <given-names>MK</given-names>
              </name>
            </person-group>
            <article-title>Update to CDC's U.S. Medical Eligibility Criteria for Contraceptive Use, 2016: Revised Recommendations for the Use of Hormonal Contraception Among Women at High Risk for HIV Infection.</article-title>
            <source>MMWR Morb Mortal Wkly Rep</source>
            <year>2017</year>
            <month>Sep</month>
            <day>22</day>
            <volume>66</volume>
            <issue>37</issue>
            <fpage>990</fpage>
            <page-range>990-994</page-range>
            <pub-id pub-id-type="pmid">28934178</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24900.r40">
          <label>40</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bernstein</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Pohost</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Progesterone, progestins, and the heart.</article-title>
            <source>Rev Cardiovasc Med</source>
            <year>2010</year>
            <season>Fall</season>
            <volume>11</volume>
            <issue>4</issue>
            <fpage>228</fpage>
            <page-range>228-36</page-range>
            <pub-id pub-id-type="pmid">21389912</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24900.r41">
          <label>41</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Manson</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>Chlebowski</surname>
                <given-names>RT</given-names>
              </name>
              <name>
                <surname>Stefanick</surname>
                <given-names>ML</given-names>
              </name>
              <name>
                <surname>Aragaki</surname>
                <given-names>AK</given-names>
              </name>
              <name>
                <surname>Rossouw</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>Prentice</surname>
                <given-names>RL</given-names>
              </name>
              <name>
                <surname>Anderson</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Howard</surname>
                <given-names>BV</given-names>
              </name>
              <name>
                <surname>Thomson</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>LaCroix</surname>
                <given-names>AZ</given-names>
              </name>
              <name>
                <surname>Wactawski-Wende</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Jackson</surname>
                <given-names>RD</given-names>
              </name>
              <name>
                <surname>Limacher</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Margolis</surname>
                <given-names>KL</given-names>
              </name>
              <name>
                <surname>Wassertheil-Smoller</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Beresford</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>Cauley</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Eaton</surname>
                <given-names>CB</given-names>
              </name>
              <name>
                <surname>Gass</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Hsia</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Johnson</surname>
                <given-names>KC</given-names>
              </name>
              <name>
                <surname>Kooperberg</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Kuller</surname>
                <given-names>LH</given-names>
              </name>
              <name>
                <surname>Lewis</surname>
                <given-names>CE</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Martin</surname>
                <given-names>LW</given-names>
              </name>
              <name>
                <surname>Ockene</surname>
                <given-names>JK</given-names>
              </name>
              <name>
                <surname>O'Sullivan</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Powell</surname>
                <given-names>LH</given-names>
              </name>
              <name>
                <surname>Simon</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Van Horn</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Vitolins</surname>
                <given-names>MZ</given-names>
              </name>
              <name>
                <surname>Wallace</surname>
                <given-names>RB</given-names>
              </name>
            </person-group>
            <article-title>Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the Women's Health Initiative randomized trials.</article-title>
            <source>JAMA</source>
            <year>2013</year>
            <month>Oct</month>
            <day>02</day>
            <volume>310</volume>
            <issue>13</issue>
            <fpage>1353</fpage>
            <page-range>1353-68</page-range>
            <pub-id pub-id-type="pmid">24084921</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24900.r42">
          <label>42</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bahamondes</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Perrotti</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Castro</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Fa&#x000fa;ndes</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Petta</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Bedone</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Forearm bone density in users of Depo-Provera as a contraceptive method.</article-title>
            <source>Fertil Steril</source>
            <year>1999</year>
            <month>May</month>
            <volume>71</volume>
            <issue>5</issue>
            <fpage>849</fpage>
            <page-range>849-52</page-range>
            <pub-id pub-id-type="pmid">10231044</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24900.r43">
          <label>43</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hersi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Irvine</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Gupta</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Gomes</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Birkett</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Krewski</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Risk factors associated with the onset and progression of Alzheimer's disease: A systematic review of the evidence.</article-title>
            <source>Neurotoxicology</source>
            <year>2017</year>
            <month>Jul</month>
            <volume>61</volume>
            <fpage>143</fpage>
            <page-range>143-187</page-range>
            <pub-id pub-id-type="pmid">28363508</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24900.r44">
          <label>44</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Maki</surname>
                <given-names>PM</given-names>
              </name>
              <name>
                <surname>Henderson</surname>
                <given-names>VW</given-names>
              </name>
            </person-group>
            <article-title>Hormone therapy, dementia, and cognition: the Women's Health Initiative 10 years on.</article-title>
            <source>Climacteric</source>
            <year>2012</year>
            <month>Jun</month>
            <volume>15</volume>
            <issue>3</issue>
            <fpage>256</fpage>
            <page-range>256-62</page-range>
            <pub-id pub-id-type="pmid">22612612</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24900.r45">
          <label>45</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Trimble</surname>
                <given-names>CL</given-names>
              </name>
              <name>
                <surname>Method</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Leitao</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Lu</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Ioffe</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Hampton</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Higgins</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Zaino</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Mutter</surname>
                <given-names>GL</given-names>
              </name>
              <collab>Society of Gynecologic Oncology Clinical Practice Committee</collab>
            </person-group>
            <article-title>Management of endometrial precancers.</article-title>
            <source>Obstet Gynecol</source>
            <year>2012</year>
            <month>Nov</month>
            <volume>120</volume>
            <issue>5</issue>
            <fpage>1160</fpage>
            <page-range>1160-75</page-range>
            <pub-id pub-id-type="pmid">23090535</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24900.r46">
          <label>46</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Guay</surname>
                <given-names>DR</given-names>
              </name>
            </person-group>
            <article-title>Drug treatment of paraphilic and nonparaphilic sexual disorders.</article-title>
            <source>Clin Ther</source>
            <year>2009</year>
            <month>Jan</month>
            <volume>31</volume>
            <issue>1</issue>
            <fpage>1</fpage>
            <page-range>1-31</page-range>
            <pub-id pub-id-type="pmid">19243704</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24900.r47">
          <label>47</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Reilly</surname>
                <given-names>DR</given-names>
              </name>
              <name>
                <surname>Delva</surname>
                <given-names>NJ</given-names>
              </name>
              <name>
                <surname>Hudson</surname>
                <given-names>RW</given-names>
              </name>
            </person-group>
            <article-title>Protocols for the use of cyproterone, medroxyprogesterone, and leuprolide in the treatment of paraphilia.</article-title>
            <source>Can J Psychiatry</source>
            <year>2000</year>
            <month>Aug</month>
            <volume>45</volume>
            <issue>6</issue>
            <fpage>559</fpage>
            <page-range>559-63</page-range>
            <pub-id pub-id-type="pmid">10986575</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24900.r48">
          <label>48</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Grissinger</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Tall man letters are gaining wide acceptance.</article-title>
            <source>P T</source>
            <year>2012</year>
            <month>Mar</month>
            <volume>37</volume>
            <issue>3</issue>
            <fpage>132</fpage>
            <page-range>132-48</page-range>
            <pub-id pub-id-type="pmid">22605902</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24900.r49">
          <label>49</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>James</surname>
                <given-names>RC</given-names>
              </name>
              <name>
                <surname>Britt</surname>
                <given-names>JK</given-names>
              </name>
              <name>
                <surname>Halmes</surname>
                <given-names>NC</given-names>
              </name>
              <name>
                <surname>Guzelian</surname>
                <given-names>PS</given-names>
              </name>
            </person-group>
            <article-title>Evidence-based causation in toxicology: A 10-year retrospective.</article-title>
            <source>Hum Exp Toxicol</source>
            <year>2015</year>
            <month>Dec</month>
            <volume>34</volume>
            <issue>12</issue>
            <fpage>1245</fpage>
            <page-range>1245-52</page-range>
            <pub-id pub-id-type="pmid">26614812</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24900.r50">
          <label>50</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sharts-Hopko</surname>
                <given-names>NC</given-names>
              </name>
            </person-group>
            <article-title>Depo-Provera.</article-title>
            <source>MCN Am J Matern Child Nurs</source>
            <year>1993</year>
            <season>Mar-Apr</season>
            <volume>18</volume>
            <issue>2</issue>
            <fpage>128</fpage>
            <pub-id pub-id-type="pmid">8492647</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
